Compare AMCR & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMCR | DGX |
|---|---|---|
| Founded | 1926 | 1967 |
| Country | Switzerland | United States |
| Employees | 77000 | N/A |
| Industry | Miscellaneous manufacturing industries | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3B | 20.5B |
| IPO Year | N/A | 1996 |
| Metric | AMCR | DGX |
|---|---|---|
| Price | $8.41 | $173.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | $10.40 | ★ $196.69 |
| AVG Volume (30 Days) | ★ 17.0M | 904.9K |
| Earning Date | 02-03-2026 | 01-29-2026 |
| Dividend Yield | ★ 6.24% | 1.84% |
| EPS Growth | N/A | ★ 14.49 |
| EPS | 0.32 | ★ 8.51 |
| Revenue | ★ $17,401,000,000.00 | $10,850,000,000.00 |
| Revenue This Year | $57.16 | $12.37 |
| Revenue Next Year | $1.28 | $3.52 |
| P/E Ratio | $26.00 | ★ $20.38 |
| Revenue Growth | ★ 28.42 | 13.74 |
| 52 Week Low | $7.67 | $148.70 |
| 52 Week High | $10.45 | $197.55 |
| Indicator | AMCR | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 54.58 | 32.93 |
| Support Level | $8.25 | $174.63 |
| Resistance Level | $8.46 | $176.37 |
| Average True Range (ATR) | 0.11 | 2.23 |
| MACD | 0.01 | -0.42 |
| Stochastic Oscillator | 83.93 | 11.55 |
Amcor is a global producer of plastic packaging primarily for the fast-moving consumer goods industry. About 90% of earnings are exposed to the flexible packaging business. This is soft disposable plastic for a variety of food, drink, healthcare, and hygiene products. The remainder of earnings are from the Latin and North American rigids business, which is primarily beverage bottling for the soft drink industry. Operating in more than 35 countries, Amcor has market share in its established regions of North America, Latin America, Europe, and Asia-Pacific. About half of group sales are derived from North America and the remainder is split equally between Western Europe and emerging markets. Australia and New Zealand sales make up less than 5% of group sales.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.